Amyotrophic Lateral Sclerosis Research Program
The ALSRP supports innovative research on ALS therapies, biomarkers, and clinical outcomes, emphasizing translational impact and community collaboration.
Funder: Military Health System Research Program
Due Dates (Anticipated): May 2026: Pre‑application (projected) | September 2026: Full application (by invitation, projected)
Funding Amounts: Award size varies by mechanism: $840,000–$2.8M total costs; project periods up to 2–3 years
Summary: Funds innovative, clinically relevant ALS research to accelerate new treatments, biomarker development, and therapy discovery.
Key Information: Preproposal required; full application by invitation only; strong data sharing and community engagement required.
Description
The Amyotrophic Lateral Sclerosis Research Program (ALSRP), administered by the Congressionally Directed Medical Research Programs (CDMRP) under the Defense Health Agency, supports high-impact research that aims to improve clinical outcomes and discover cures for ALS. The program emphasizes the development and validation of clinical outcomes and biomarkers, early-stage clinical trials, preclinical therapeutic validation, and novel therapy discovery. Community collaboration, strong data sharing plans, and translational research are core priorities. Multiple award mechanisms are offered, each targeting a specific stage of the ALS research pipeline.
